AxoGen, Inc., a global leader in developing and marketing innovative surgical solutions for peripheral nerves, has announced the closing of its previously announced underwritten public offering of 3,450,000 shares of its common stock, at a price to the public of $41.00 per share.
The number of shares sold by AxoGen includes an aggregate of 450,000 shares of common stock offered and sold pursuant to an option granted to the underwriters that was exercised in full. The total net proceeds from the offering for AxoGen are estimated to be approximately $132,463,000, after deducting underwriting discounts and commissions and other estimated offering expenses payable by AxoGen. AxoGen intends to use the net proceeds from the offering for long term facility and capacity expansion and general corporate purposes.
Jefferies LLC and Leerink Partners LLC acted as joint book-running managers for the offering. William Blair & Company, L.L.C and JMP Securities LLC acted as co-managers.